Curr Probl Cardiol. 2019 Mar;44(3):92-106. doi: 10.1016/j.cpcardiol.2018.04.002. Epub 2018 May 10.
Long QT syndrome (LQT) represents a heterogeneous family of cardiac electrophysiologic disorders characterized by QT prolongation and T-wave abnormalities on the electrocardiogram. It is commonly associated with syncope, however, sudden cardiac death can occur due to torsades de pointes. LQT is a clinical diagnosis and should be suspected in individuals on the basis of clinical presentation, family history and ECG characteristics. Management is focused on the prevention of syncope and ultimately sudden death. Complete cessation of symptoms is the goal. Life-style modification, beta blockers and ICD implantation are the most important therapeutic modalities in proper management of patients with LQT. Awareness should be raised regarding possible circumstances that could increase the risk of QT prolongation. Advanced age, hypokalemia, a history of heart failure, and structural heart disease are often mentioned in this context. Prudent consideration is needed before making a decision to recommend an ICD implantation in a young, active patient. Medical and/or device therapy still represent important therapeutic modalities in the management of patients with LQT with careful clinical judgement for the substrate of patients who will benefit. Insights from benchside to bedside have facilitated progress toward better therapeutic strategies, there also remains a need for tailoring management toward individuals in a mechanism-specific manner to optimize care. In addition, continued progress toward fundamental understanding of mechanisms of ion channel function and drug-channel interaction will guide the development of more effective, mechanism-based molecular agents in the treatment of LQT.
长 QT 综合征 (LQT) 代表一组异质性的心脏电生理疾病,其特征为心电图上 QT 间期延长和 T 波异常。它通常与晕厥有关,但由于尖端扭转型室性心动过速,也可能发生心脏性猝死。LQT 是一种临床诊断,应根据临床表现、家族史和心电图特征怀疑个体存在该疾病。管理的重点是预防晕厥和最终的心脏性猝死。完全停止症状是目标。生活方式的改变、β受体阻滞剂和植入式心脏复律除颤器是 LQT 患者适当管理中最重要的治疗方式。应该注意可能增加 QT 间期延长风险的情况。在这种情况下,常提到年龄较大、低钾血症、心力衰竭史和结构性心脏病。在决定推荐年轻、活跃的患者植入 ICD 之前,需要谨慎考虑。在对将从中获益的患者的基础进行仔细的临床判断的情况下,药物和/或器械治疗仍然是 LQT 患者管理的重要治疗方式。从实验室到临床的深入了解促进了更好的治疗策略的发展,但仍需要针对个体的特定机制进行管理调整,以优化治疗。此外,继续深入了解离子通道功能和药物-通道相互作用的机制将指导更有效、基于机制的分子药物的开发,以治疗 LQT。